Agreed - and at least with this announcement it means that any doubt about progressing to phase two trials for PMS and probably Pitt Hopkins, has now been removed.
Also - NNZ-2591 is a more superior drug than trofinetide, according to Jon Pilcher....
"Yes trofinetide and NNZ-2591 both originate from Dame Margaret Brimble's work in Auckland. They are analogs of two different molecules - glycine proline glutamate (GPE) and cyclic glycine proline (cGP) respectively. Each plays a role in the metabolism of IGF-1 in the brain. The desired outcome of using the power of IGF-1 in the brain is the same, but with a different mechanism to achieve it. They also have different properties as drugs, with 2591 clearly superior in a few ways."
Also ...
"In the near term we think there are better opportunities with the current indications and potentially many more neurodevelopmental disorders."
I am confident that the results looming from the ensuing trials for Angelmans, Pitt Hopkins and PMS trials will outdo the Retts trials. And the market for those alone is more than 5 times the value for Retts...
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)